May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Interim Analysis of a Randomized Dose-Escalation Trial of Locally-Administered Sirolimus to Treat Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Author Affiliations & Notes
  • P. U. Dugel
    Retinal Consultants of Arizona, Phoenix, Arizona
  • H. Quiroz-Mercado
    APEC Hospital, Mexico City, Mexico
  • D. M. Kleinman
    University of Rochester Eye Institute, Rochester, New York
  • D. A. Weber
    MacuSight, Inc., Union City, CA, California
  • G. A. Williams
    Associated Retinal Consultants, Beaumont Eye Institute, Royal Oak, Michigan
  • J. A. Haller
    Wills Eye Institute, Jefferson Medical College, Philadelphia, Pennsylvania
  • M. S. Blumenkranz
    Department of Ophthalmology, Stanford University, Stanford, California
  • Footnotes
    Commercial Relationships  P.U. Dugel, MacuSight, Inc., C; H. Quiroz-Mercado, MacuSight, Inc., C; D.M. Kleinman, MacuSight, Inc., I; MacuSight, Inc., C; MacuSight, Inc., P; D.A. Weber, MacuSight, Inc., I; MacuSight, Inc., E; MacuSight, Inc., P; G.A. Williams, MacuSight, Inc., C; J.A. Haller, MacuSight, Inc., C; M.S. Blumenkranz, MacuSight, Inc., C.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 582. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. U. Dugel, H. Quiroz-Mercado, D. M. Kleinman, D. A. Weber, G. A. Williams, J. A. Haller, M. S. Blumenkranz; Interim Analysis of a Randomized Dose-Escalation Trial of Locally-Administered Sirolimus to Treat Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):582. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Sirolimus (rapamycin) is a specific inhibitor of the mammalian target of rapamycin (mTOR), a regulatory protein kinase which regulates cell growth, proliferation, motility, and survival. Sirolimus has broad activity that includes anti-angiogenic, anti-fibrotic, anti-proliferative, and anti-inflammatory effects and has shown efficacy in multiple preclinical choroidal neovascularization (CNV) models. The purpose of this study was to evaluate the safety and pharmacological activity of a proprietary liquid depot-forming formulation of sirolimus in patients with sub-foveal CNV due to age-related macular degeneration (AMD).

Methods: : A multi-center, open-label Phase 1 dose-escalation study was conducted in 30 patients with newly diagnosed, treatment-naïve CNV having best-corrected visual acuity (BCVA) of 20/40 - 20/200. Patients were randomly assigned (five per dose group) to receive either a single intravitreal (IVT) (44, 110, 176 µg) or a single subconjunctival (SCJ) (220, 440, 880 µg) sirolimus injection. BCVA was assessed by ETDRS at 4 meters and central retinal lesion thickness as determined by OCT was interpreted by an independent reading center at 14 and 45 days.

Results: : No dose-limiting toxicities were encountered and no systemic adverse events probably or possibly related to the study drug were reported. CNV lesion characteristics at baseline were 17% predominantly classic, 50% minimally classic, and 33% occult with no classic component. The mean baseline BCVA was 48 letters and mean baseline OCT thickness was 457 µm. Interim results showed mean BCVA improvements of 7.6 ± 9.9 and 4.0 ± 12.6 letters and mean OCT reductions of 126 ± 229 and 77 ± 112 µm at 14 and 45 days, respectively, following a single 44 µg IVT injection. Mean BCVA improvements of 5.2 ± 6.3 and 2.4 ± 5.2 letters and mean OCT reductions of 58 ± 107 and 54 ± 130 µm were observed at 14 and 45 days, respectively, following a single 440 µg SCJ injection.

Conclusions: : No safety issues and promising efficacy signals were observed following a single subconjunctival or intravitreal injection of sirolimus in patients with treatment-naïve CNV secondary to AMD.

Clinical Trial: : - FDA Phase 1 Study

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×